BR3409-1

DRUG2 trials

Sponsors

Boryung Pharmaceutical Co., Ltd

Conditions

Type 2 Diabetes

Phase 1

A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fasting Conditions

CompletedNCT06879158

Boryung Pharmaceutical Co., LtdType 2 Diabetes

Start: 2024-11-10End: 2025-01-26Updated: 2025-03-17

A Study to Evaluate the Pharmacokinetics and Safety of BR3409 and Co-administration of BR3409-1 and BR3409-2 in Healthy Volunteers Under Fed Conditions

CompletedNCT06879132

Boryung Pharmaceutical Co., LtdType 2 Diabetes

Start: 2024-11-05End: 2024-12-07Updated: 2025-03-17